Accession Number:

AD1043767

Title:

Anti-scar Treatment for Deep Partial-thickness Burn Wounds

Descriptive Note:

Technical Report,30 Sep 2016,29 Sep 2017

Corporate Author:

The Geneva Foundation Tacoma United States

Personal Author(s):

• Leung, Kai

Report Date:

2017-10-01

Pagination or Media Count:

20.0

Abstract:

The FDA-approved drug pirfenidone is an anti-inflammatoryanti-fibrosis drug indicated for pulmonary fibrosis that we hypothesize can diminish scarring when applied topically to deep partial-thickness burn wounds in two animal models. The long-term objective is to learn to effectively use pirfenidone with regard to dosage, formulation and timing of treatment of burn wounds, such that animal studies will likely translate to the clinic. The objective of this proposal is to evaluate pirfenidone for efficacy in reducing fibrosis and scarring parameters in mouse and porcine models of deep partial-thickness burn wounds. The dosage formulation and schedule of treatment will be optimized and molecular markers of inflammation, angiogenesis, wound healing, and fibrosis will be correlated with scar reduction.

Descriptors:

• BURNS
• DRUG THERAPY
• Fibrosis
• SCARS
• MODELS
• INFLAMMATION
• THERAPY

Subject Categories:

• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE